Живи долго! Научный подход к долгой молодости и здоровью

3652

Curry SJ, Krist AH, Owens DK, et al. Risk assessment for cardiovascular disease with nontraditional risk factors: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(3):272–80. https://pubmed.ncbi.nlm.nih.gov/29998297/

3653

Diamond DM, de Lorgeril M, Kendrick M, Ravnskov U, Rosch PJ. Formal comment on “Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease.” PLoS One. 2019;14(1):e0205138. https://pubmed.ncbi.nlm.nih.gov/30653537/

3654

Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–83. https://pubmed.ncbi.nlm.nih.gov/24079289/

3655

Ward NC, Watts GF, Eckel RH. Statin toxicity: mechanistic insights and clinical implications. Circ Res. 2019;124(2):328–50. https://pubmed.ncbi.nlm.nih.gov/30653440/

3656

Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as treatment for statin-associated muscle symptoms – a good idea, but…. Adv Nutr. 2018;9(4):519S-23S. https://pubmed.ncbi.nlm.nih.gov/30032220/

3657

Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24–34. https://pubmed.ncbi.nlm.nih.gov/25440725/

3658

Armour R, Zhou L. Outcomes of statin myopathy after statin withdrawal. J Clin Neuromuscul Dis. 2013;14(3):103–9. https://pubmed.ncbi.nlm.nih.gov/23492461/

3659

Majeed A, Molokhia M. Urgent need to establish the true incidence of the side effects of statins. BMJ. 2014;348:g3650. https://pubmed.ncbi.nlm.nih.gov/24920685/

3660

Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21(4):464–74. https://pubmed.ncbi.nlm.nih.gov/24623264/

3661

Climent E, Benaiges D, Pedro-Botet J. Statin treatment and increased diabetes risk. Possible mechanisms. Clínica e Investigación en Arteriosclerosis. 2019;31(5):228–32. https://pubmed.ncbi.nlm.nih.gov/30737072/

3662

Mansi IA, English J, Zhang S, Mortensen EM, Halm EA. Long-term outcomes of short-term statin use in healthy adults: a retrospective cohort study. Drug Saf. 2016;39(6):543–59. https://pubmed.ncbi.nlm.nih.gov/26979831/

3663

The Panel on Food Additives and Nutrient Sources, Aggett P, Aguilar F, et al. Scientific opinion on the safety of monacolins in red yeast rice. EFSA J. 2018;16(80):5368. https://pubmed.ncbi.nlm.nih.gov/32626016/

3664

Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170(19):1722–7. https://pubmed.ncbi.nlm.nih.gov/20975018/

3665

Righetti L, Dall’Asta C, Bruni R. Risk assessment of RYR food supplements: perception vs. reality. Front Nutr. 2021;8:792529. https://pubmed.ncbi.nlm.nih.gov/34950692/

3666

Murphy SL, Kochanek KD, Xu J, Arias E. Mortality in the United States, 2020. NCHS Data Brief, No. 427. https://www.cdc.gov/nchs/products/databriefs/db427.htm. Published December 2021. Accessed January 3, 2023.; https://www.cdc.gov/nchs/products/databriefs/db427.htm

3667

Jukema JW, Cannon CP, de Craen AJM, Westendorp RGJ, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012;60(10):875–81. https://pubmed.ncbi.nlm.nih.gov/22902202/

3668

Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81. https://pubmed.ncbi.nlm.nih.gov/30580575/

3669

Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA. 2016;316(19):1979–81. https://pubmed.ncbi.nlm.nih.gov/27838702/

3670

Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280(23):2001–7. https://pubmed.ncbi.nlm.nih.gov/9863851/

3671

Kelly J, Karlsen M, Steinke G. Type 2 diabetes remission and lifestyle medicine: a position statement from the American College of Lifestyle Medicine. Am J Lifestyle Med. 2020;14(4):406–19. https://pubmed.ncbi.nlm.nih.gov/33281521/

3672

Esselstyn CB Jr, Gendy G, Doyle J, Golubic M, Roizen MF. A way to reverse CAD? J Fam Pract. 2014;63(7):356–64b. https://pubmed.ncbi.nlm.nih.gov/25198208/

3673

Hochholzer W, Giugliano RP. Lipid lowering goals: back to nature? Ther Adv Cardiovasc Dis. 2010;4(3):185–91. https://pubmed.ncbi.nlm.nih.gov/20400493/

3674

Steinberg D, Witztum JL. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci U S A. 2009;106(24):9546–7. https://pubmed.ncbi.nlm.nih.gov/19506257/

3675

Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161–5. https://pubmed.ncbi.nlm.nih.gov/15654334/

3676

Jaworski K, Jankowski P, Kosior DA. PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade. Arch Med Sci. 2017;13(4):914–29. https://pubmed.ncbi.nlm.nih.gov/28721159/

3677

Qamar A, Bhatt DL. Effect of low cholesterol on steroid hormones and vitamin E levels: just a theory or real concern? Circ Res. 2015;117(8):662–4. https://pubmed.ncbi.nlm.nih.gov/26405182/

3678

Blom DJ, Djedjos CS, Monsalvo ML, et al. Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ Res. 2015;117(8):731–41. https://pubmed.ncbi.nlm.nih.gov/26228031/

3679

Qamar A, Libby P. Low-density lipoprotein cholesterol after an acute coronary syndrome: how low to go? Curr Cardiol Rep. 2019;21(8):77. https://pubmed.ncbi.nlm.nih.gov/31250329/

3680

Hochholzer W, Giugliano RP. Lipid lowering goals: back to nature? Ther Adv Cardiovasc Dis. 2010;4(3):185–91. https://pubmed.ncbi.nlm.nih.gov/20400493/

3681

Glueck CJ, Gartside P, Fallat RW, Sielski J, Steiner PM. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med. 1976;88(6):941–57. https://pubmed.ncbi.nlm.nih.gov/186545/

3682

Packard CJ. LDL cholesterol: How low to go? Trends Cardiovasc Med. 2018;28(5):348–54. https://pubmed.ncbi.nlm.nih.gov/29336946/

3683

Gotto AM. Low-density lipoprotein cholesterol and cardiovascular risk reduction: how low is low enough without causing harm? JAMA Cardiol. 2018;3(9):802–3. https://pubmed.ncbi.nlm.nih.gov/30073330/

3684

Packard CJ. LDL cholesterol: How low to go? Trends Cardiovasc Med. 2018;28(5):348–54. https://pubmed.ncbi.nlm.nih.gov/29336946/

3685

Steinberg D. The cholesterol controversy is over. Why did it take so long? Circulation. 1989;80(4):1070–8. https://pubmed.ncbi.nlm.nih.gov/2676235/

3686

Morgan DJ, Dhruva SS, Coon ER, Wright SM, Korenstein D. 2018 update on medical overuse. JAMA Intern Med. 2019;179(2):240–6. https://pubmed.ncbi.nlm.nih.gov/30508032/

3687

Lyu H, Xu T, Brotman D, et al. Overtreatment in the United States. PLoS One. 2017;12(9):e0181970. https://pubmed.ncbi.nlm.nih.gov/28877170/

3688

Rothberg MB, Scherer L, Kashef MA, et al. The effect of information presentation on beliefs about the benefits of elective percutaneous coronary intervention. JAMA Intern Med. 2014;174(10):1623–9. https://pubmed.ncbi.nlm.nih.gov/25156687/

3689

Rothberg MB, Sivalingam SK, Ashraf J, et al. Summaries for patients: patients’ and cardiologists’ beliefs about a common heart procedure. Ann Intern Med. 2010;153(5):I46. https://pubmed.ncbi.nlm.nih.gov/20820040/

3690

Laukkanen JA, Kunutsor SK, Lavie CJ. Percutaneous coronary intervention versus medical therapy in the treatment of stable coronary artery disease: an updated meta-analysis of contemporary randomized controlled trials. J Invasive Cardiol. 2021;33(8):E647–57. https://pubmed.ncbi.nlm.nih.gov/34338654/

3691

Harvard Heart Letter. COURAGE to make choices. Harvard Health Publishing. https://www.health.harvard.edu/newsletter_article/courage-to-make-choices. Published June 1, 2007. Accessed April 5, 2022.; https://www.health.harvard.edu/newsletter_article/courage-to-make-choices

3692

Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31–40. https://pubmed.ncbi.nlm.nih.gov/29103656/

3693

Kolata G. ‘Unbelievable’: heart stents fail to ease chest pain. The New York Times. https://www.nytimes.com/2017/11/02/health/heart-disease-stents.html. Published November 2, 2017. Accessed April 5, 2022.; https://www.nytimes.com/2017/11/02/health/heart-disease-stents.html

3694

Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31–40. https://pubmed.ncbi.nlm.nih.gov/29103656/

3695

Doenst T, Haverich A, Serruys P, et al. PCI and CABG for treating stable coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2019;73(8):964–76. https://pubmed.ncbi.nlm.nih.gov/30819365/

3696

Rothberg MB. Coronary artery disease as clogged pipes: a misconceptual model. Circ Cardiovasc Qual Outcomes. 2013;6(1):129–32. https://pubmed.ncbi.nlm.nih.gov/23322809/

3697

Trumbo PR, Shimakawa T. Tolerable upper intake levels for trans fat, saturated fat, and cholesterol. Nutr Rev. 2011;69(5):270–8. https://pubmed.ncbi.nlm.nih.gov/21521229/

3698

World Health Organization. Countdown to 2023: WHO report on global trans-fat elimination 2021. Geneva: 2021.; https://www.who.int/publications/i/item/9789240031876

3699

Wanders AJ, Zock PL, Brouwer IA. Trans fat intake and its dietary sources in general populations worldwide: a systematic review. Nutrients. 2017;9(8):E840. https://pubmed.ncbi.nlm.nih.gov/28783062/

3700

Kahle L, Krebs-Smith SM, Reedy J, Rodgers AB, Signes C. Identification of top food sources of various food components. Epidemiology and Genomics Research Program. https://epi.grants.cancer.gov/diet/foodsources/top-food-sources-report-02212020.pdf. Updated November 30, 2019. Accessed April 5, 2022.; https://epi.grants.cancer.gov/diet/foodsources/top-food-sources-report-02212020.pdf

3701

Xu Z, McClure ST, Appel LJ. Dietary cholesterol intake and sources among U.S. adults: results from National Health and Nutrition Examination Surveys (NHANES), 2001–2014. Nutrients. 2018;10(6):E771. https://pubmed.ncbi.nlm.nih.gov/29903993/

3702

Kahle L, Krebs-Smith SM, Reedy J, Rodgers AB, Signes C. Identification of top food sources of various food components. Epidemiology and Genomics Research Program. https://epi.grants.cancer.gov/diet/foodsources/top-food-sources-report-02212020.pdf. Updated November 30, 2019. Accessed April 5, 2022.; https://epi.grants.cancer.gov/diet/foodsources/top-food-sources-report-02212020.pdf

3703

Riccardi G, Giosuè A, Calabrese I, Vaccaro O. Dietary recommendations for prevention of atherosclerosis. Cardiovasc Res. 2022;118(5):1188–204. https://pubmed.ncbi.nlm.nih.gov/34229346/

3704

Кокрейновская база данных систематических обзоров и метаанализов, которые обобщают и интерпретируют результаты медицинских исследований. – Примеч. ред.

3705

Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2015;(6):CD011737. https://pubmed.ncbi.nlm.nih.gov/26068959/

3706

Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2017;136(3):e1–30. https://pubmed.ncbi.nlm.nih.gov/28620111/

3707

Hughes S. AHA issues ‘Presidential Advisory’ on harms of saturated fat. Medscape. https://www.medscape.com/viewarticle/881689. Published June 15, 2017. Accessed April 3, 2022.; https://www.medscape.com/viewarticle/881689

3708

Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2017;136(3):e1–30. https://pubmed.ncbi.nlm.nih.gov/28620111/

3709

Bergeron N, Chiu S, Williams PT, M King S, Krauss RM. Effects of red meat, white meat, and nonmeat protein sources on atherogenic lipoprotein measures in the context of low compared with high saturated fat intake: a randomized controlled trial. Am J Clin Nutr. 2019;110(1):24–33. https://pubmed.ncbi.nlm.nih.gov/31161217/

3710

Maki KC, Van Elswyk ME, Alexander DD, Rains TM, Sohn EL, McNeill S. A meta-analysis of randomized controlled trials that compare the lipid effects of beef versus poultry and/or fish consumption. J Clin Lipidol. 2012;6(4):352–61. https://pubmed.ncbi.nlm.nih.gov/22836072/

3711

Connor WE, Connor SL. Dietary cholesterol and coronary heart disease. Curr Atheroscler Rep. 2002;4(6):425–32. https://pubmed.ncbi.nlm.nih.gov/12361489/

3712

Khalighi Sikaroudi M, Soltani S, Kolahdouz-Mohammadi R, et al. The responses of different dosages of egg consumption on blood lipid profile: an updated systematic review and meta-analysis of randomized clinical trials. J Food Biochem. 2020;44(8):e13263. https://pubmed.ncbi.nlm.nih.gov/32524644/

3713

Barnard ND, Long MB, Ferguson JM, Flores R, Kahleova H. Industry funding and cholesterol research: a systematic review. Am J Lifestyle Med. 2021;15(2):165–72. https://pubmed.ncbi.nlm.nih.gov/33786032/

3714

Choi Y, Chang Y, Lee JE, et al. Egg consumption and coronary artery calcification in asymptomatic men and women. Atherosclerosis. 2015;241(2):305–12. https://pubmed.ncbi.nlm.nih.gov/26062990/

3715

Zhong VW, Van Horn L, Cornelis MC, et al. Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality. JAMA. 2019;321(11):1081–95. https://pubmed.ncbi.nlm.nih.gov/30874756/

3716

Abbasi J. Study puts eggs and dietary cholesterol back on the radar. JAMA. 2019;321(20):1959–61. https://pubmed.ncbi.nlm.nih.gov/31066864/

3717

Physicians Comm for Responsible Med v. Vilsack, № 16-cv-00069-LB, 2016 US Dist LEXIS 141489, 2016 WL 5930585 (ND Cal 2016).; https://casetext.com/case/physicians-comm-for-responsible-med-v-vilsack-2

3718

U.S. Department of Agriculture, U.S. Department of Health and Human Services. Dietary guidelines for Americans, 2015–2020. 8th ed. http://health.gov/dietaryguidelines/2015/guidelines/. Published December 2015. Accessed May 25, 2022; https://health.gov/dietaryguidelines/2015/guidelines/

3719

U.S. Department of Agriculture, U.S. Department of Health and Human Services. Dietary guidelines for Americans, 2020–2025. 9th ed. https://www.dietaryguidelines.gov/sites/default/files/2020–12/Dietary_Guidelines_for_Americans_2020–2025.pdf. Published December 2020. Accessed April 5, 2022.; https://www.dietaryguidelines.gov/sites/default/files/2020-12/Dietary_Guidelines_for_Americans_2020-2025.pdf

3720

Trumbo PR, Shimakawa T. Tolerable upper intake levels for trans fat, saturated fat, and cholesterol. Nutr Rev. 2011;69(5):270–8. https://pubmed.ncbi.nlm.nih.gov/21521229/

3721

David Spence J. Dietary cholesterol and egg yolk should be avoided by patients at risk of vascular disease. J Transl Int Med. 2016;4(1):20–4. https://pubmed.ncbi.nlm.nih.gov/28191513/

3722

Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): an independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J. 2019;71(2):99–112. https://pubmed.ncbi.nlm.nih.gov/31280836/

3723

Kotani K, Serban MC, Penson P, Lippi G, Banach M. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – some answers and still many questions. Crit Rev Clin Lab Sci. 2016;53(6):370–8. https://pubmed.ncbi.nlm.nih.gov/27173621/

3724

Stulnig TM, Morozzi C, Reindl-Schwaighofer R, Stefanutti C. Looking at Lp(a) and related cardiovascular risk: from scientific evidence and clinical practice. Curr Atheroscler Rep. 2019;21(10):37. https://pubmed.ncbi.nlm.nih.gov/31350625/

3725

Kostner KM, Kostner GM, Wierzbicki AS. Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate. Atherosclerosis. 2018;274:16–22. https://pubmed.ncbi.nlm.nih.gov/29747086/

3726

Stender S. In equal amounts, the major ruminant trans fatty acid is as bad for LDL cholesterol as industrially produced trans fatty acids, but the latter are easier to remove from foods. Am J Clin Nutr. 2015;102(6):1301–2. https://pubmed.ncbi.nlm.nih.gov/26561633/

3727

Gebauer SK, Destaillats F, Dionisi F, Krauss RM, Baer DJ. Vaccenic acid and trans fatty acid isomers from partially hydrogenated oil both adversely affect LDL cholesterol: a double-blind, randomized controlled trial. Am J Clin Nutr. 2015;102(6):1339–46. https://pubmed.ncbi.nlm.nih.gov/26561632/

3728

Вариант вегетарианства, при котором разрешены не только продукты растительного происхождения, но также молоко и яйца. – Примеч. ред.

3729

Masarei JR, Rouse IL, Lynch WJ, Robertson K, Vandongen R, Beilin LJ. Effects of a lacto-ovo vegetarian diet on serum concentrations of cholesterol, triglyceride, HDL–C, HDL2-C, HDL3-C, apoprotein-B, and Lp(a). Am J Clin Nutr. 1984;40(3):468–78. https://pubmed.ncbi.nlm.nih.gov/6089540/

3730

Sahebkar A, Katsiki N, Ward N, Reiner Ž. Flaxseed supplementation reduces plasma lipoprotein(a) levels: a meta-analysis. Altern Ther Health Med. 2021;27(3):50–3. https://pubmed.ncbi.nlm.nih.gov/31634874/

3731

Biswas TK, Chakrabarti S, Pandit S, Jana U, Dey SK. Pilot study evaluating the use of Emblica officinalis standardized fruit extract in cardio-respiratory improvement and antioxidant status of volunteers with smoking history. J Herb Med. 2014;4(4):188–94. https://www.sciencedirect.com/science/article/abs/pii/S2210803314000633

3732

Najjar RS, Moore CE, Montgomery BD. Consumption of a defined, plant-based diet reduces lipoprotein(a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks. Clin Cardiol. 2018;41(8):1062–8. https://pubmed.ncbi.nlm.nih.gov/30014498/

3733

Berk KA, Yahya R, Verhoeven AJM, et al. Effect of diet-induced weight loss on lipoprotein(A) levels in obese individuals with and without type 2 diabetes. Diabetologia. 2017;60(6):989–97. https://pubmed.ncbi.nlm.nih.gov/28386638/

3734

Najjar RS, Moore CE, Montgomery BD. A defined, plant-based diet utilized in an outpatient cardiovascular clinic effectively treats hypercholesterolemia and hypertension and reduces medications. Clin Cardiol. 2018;41(3):307–13. https://pubmed.ncbi.nlm.nih.gov/29575002/

3735

Najjar RS, Moore CE, Montgomery BD. Consumption of a defined, plant-based diet reduces lipoprotein(a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks. Clin Cardiol. 2018;41(8):1062–8. https://pubmed.ncbi.nlm.nih.gov/30014498/

3736

Li H, Zeng X, Wang Y, et al. A prospective study of healthful and unhealthful plant-based diet and risk of overall and cause-specific mortality. Eur J Nutr. 2022;61(1):387–98. https://pubmed.ncbi.nlm.nih.gov/34379193/

3737

Keaver L, Ruan M, Chen F, et al. Plant- and animal-based diet quality and mortality among US adults: a cohort study. Br J Nutr. 2021;125(12):1405–15. https://pubmed.ncbi.nlm.nih.gov/32943123/

3738

Spiegelhalter D. Using speed of ageing and “microlives” to communicate the effects of lifetime habits and environment. BMJ. 2012;345:e8223. https://pubmed.ncbi.nlm.nih.gov/23247978/

3739

Jafari S, Hezaveh E, Jalilpiran Y, et al. Plant-based diets and risk of disease mortality: a systematic review and meta-analysis of cohort studies. Crit Rev Food Sci Nutr. Published online May 6, 2021:1–13.; https://pubmed.ncbi.nlm.nih.gov/33951994/

3740

Remde A, DeTurk SN, Almardini A, Steiner L, Wojda T. Plant-predominant eating patterns – how effective are they for treating obesity and related cardiometabolic health outcomes? – a systematic review. Nutr Rev. 2022;80(5):1094–104. https://pubmed.ncbi.nlm.nih.gov/34498070/

3741

Benatar JR, Stewart RAH. Cardiometabolic risk factors in vegans; a meta-analysis of observational studies. PLoS One. 2018;13(12):e0209086. https://pubmed.ncbi.nlm.nih.gov/30571724/

3742

Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term low-calorie low-protein vegan diet and endurance exercise are associated with low cardiometabolic risk. Rejuvenation Res. 2007;10(2):225–34. https://pubmed.ncbi.nlm.nih.gov/17158430/

3743

Chen GC, Chen PY, Su YC, et al. Vascular, cognitive, and psychomental survey on elderly recycling volunteers in Northern Taiwan. Front Neurol. 2018;9:1176. https://pubmed.ncbi.nlm.nih.gov/30687225/

3744

McDougall J, Thomas LE, McDougall C, et al. Effects of 7 days on an ad libitum low-fat vegan diet: the McDougall Program cohort. Nutr J. 2014;13:99. https://pubmed.ncbi.nlm.nih.gov/25311617/

3745

Bloomer RJ, Kabir MM, Canale RE, et al. Effect of a 21 day Daniel Fast on metabolic and cardiovascular disease risk factors in men and women. Lipids Health Dis. 2010;9:94. https://pubmed.ncbi.nlm.nih.gov/20815907/

3746

Friedman SM, Barnett CH, Franki R, Pollock B, Garver B, Barnett TD. Jumpstarting health with a 15-day whole-food plant-based program. Am J Lifestyle Med. Published online April 8, 2021:155982762110063.; https://pubmed.ncbi.nlm.nih.gov/35706593/